NCT04407390View on ClinicalTrials.gov

Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2020

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2022

Conditions
COVID
Interventions
DIETARY_SUPPLEMENT

Nicotinamide riboside

The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.

DIETARY_SUPPLEMENT

Placebo

Placebo

Trial Locations (1)

2400

Bispebjerg Hospital, Copenhagen NV

Sponsors

Collaborators (1)

Elysium Health
All Listed Sponsors
collaborator

Bispebjerg Hospital

OTHER

collaborator

Elysium Health

INDUSTRY

lead

University of Copenhagen

OTHER

NCT04407390 - Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly | Biotech Hunter | Biotech Hunter